Patents by Inventor Jesper Pass

Jesper Pass has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9908944
    Abstract: The present invention relates to a method of identifying urokinase plasminogen activator (uPA) antibodies. The invention also relates to antibodies that are capable of binding uPA and which are capable of reducing or inhibiting uPA activity. Furthermore, the invention relates to uses for such antibodies, such as therapeutic and pharmaceutical uses.
    Type: Grant
    Filed: July 15, 2014
    Date of Patent: March 6, 2018
    Assignee: Novo Nordisk A/S
    Inventors: Soeren Padkjaer, Jesper Pass, Gustav Roeder, Kasper Almholt, Pernille A. Usher
  • Publication number: 20160159924
    Abstract: The present invention relates to a method of identifying urokinase plasminogen activator (uPA) antibodies. The invention also relates to antibodies that are capable of binding uPA and which are capable of reducing or inhibiting u PA activity. Furthermore, the invention relates to uses for such antibodies, such as therapeutic and pharmaceutical uses.
    Type: Application
    Filed: July 15, 2014
    Publication date: June 9, 2016
    Inventors: Soeren PADKJAER, Jesper PASS, Gustav ROEDER, Kasper ALMHOLT, Pemille A. USHER
  • Publication number: 20140194599
    Abstract: Anti-human IL20 monoclonal antibodies that can reduce IL20 mediated activation of both IL20R1/IL20R2 and IL22R1/IL20R2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods or producing such antibodies or other antigen-binding molecules. Such antibodies or other antigen-binding molecules can be used for treating various diseases and disorders, including autoimmune or inflammatory diseases or disorders.
    Type: Application
    Filed: August 21, 2013
    Publication date: July 10, 2014
    Applicant: NOVO NORDISK A/S
    Inventors: Jesper Pass, Soeren Oestergaard, Jes Thorn Clausen
  • Publication number: 20140141001
    Abstract: Anti-human IL20 monoclonal antibodies that can reduce IL20 mediated activation of both IL20R1/IL20R2 and IL22R1/IL20R2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods or producing such antibodies or other antigen-binding molecules. Such antibodies or other antigen-binding molecules can be used for treating various diseases and disorders, including autoimmune or inflammatory diseases or disorders.
    Type: Application
    Filed: August 21, 2013
    Publication date: May 22, 2014
    Applicant: NOVO NORDISK A/S
    Inventors: Jesper Pass, Soeren Oestergaard, Jes Thorn Clausen
  • Publication number: 20140056918
    Abstract: The present invention relates to antagonistic OSCAR ligands. The present invention furthermore relates to use of such ligands.
    Type: Application
    Filed: October 30, 2013
    Publication date: February 27, 2014
    Inventors: Li Guo, Svetlana Panina, Jesper Pass, Louise Hjerrild Zeuthen, Louise Maymann Nitze
  • Publication number: 20130039923
    Abstract: Anti-human IL20 monoclonal antibodies that can reduce IL20 mediated activation of both IL20R1/IL20R2 and IL22R1/IL20R2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods or producing such antibodies or other antigen-binding molecules. Such antibodies or other antigen-binding molecules can be used for treating various diseases and disorders, including autoimmune or inflammatory diseases or disorders.
    Type: Application
    Filed: September 7, 2012
    Publication date: February 14, 2013
    Applicant: Novo Nordisk A/S
    Inventors: Jesper Pass, Søren Østergaard, Jes Thorn Clausen
  • Patent number: 8287861
    Abstract: Anti-human IL20 monoclonal antibodies that can reduce IL20 mediated activation of both IL20R1/IL20R2 and IL22R1/IL20R2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods or producing such antibodies or other antigen-binding molecules. Such antibodies or other antigen-binding molecules can be used for treating various diseases and disorders, including autoimmune or inflammatory diseases or disorders.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: October 16, 2012
    Assignee: Novo Nordisk A/S
    Inventors: Jesper Pass, Søren Østergaard, Jes Thorn Clausen
  • Publication number: 20110091475
    Abstract: Anti-human IL20 monoclonal antibodies that can reduce IL20 mediated activation of both IL20R1/AL20R2 and IL22R1/AL20R2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods or producing such antibodies or other antigen-binding molecules. Such antibodies or other antigen-binding molecules can be used for treat-ing various diseases and disorders, including autoimmune or inflammatory diseases or disorders.
    Type: Application
    Filed: June 30, 2009
    Publication date: April 21, 2011
    Applicant: Novo Nordisk A/S
    Inventors: Jesper Pass, Soren Østergaard, Jes Thorn Clausen